COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 503 participants.
Also called NCT05734690
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 503 participants
- Registry
-
NCT05734690
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT05734690. Randomized; no masking; primary purpose treatment. Start 2023-05-05 (actual); primary completion 2025-05-19 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure
- Acronym
- COPILOT-HF
- Condition
- Heart Failure
- Intervention (Drug)
- SGLT2i, beta blocker, ARNI, MRA, MTD
- Intervention (Behavioral)
- Education-First
- Lead sponsor
- Brigham and Women's Hospital
- Collaborator
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05734690- Content hash
979c25d6655c3e3c684fd1827f1e2535432a1904dc19df732141b00bb7ab5738